{COMPANY NAME}
Health Screening Results
{Date} to {Date}
Report dated: {Date}
TABLE OF CONTENTS
INTRODUCTION .......................................................................................................................................................... 3
PARTICIPANT DEMOGRAPHICS ........................................................................................................................... 4
LIPID PANEL AND GYLYCEMIC RESULTS ......................................................................................................... 5
Cholesterol ................................................................................................................................................................ 6
Total Cholesterol ................................................................................................................................................. 6
HDL Cholesterol .................................................................................................................................................. 8
Cholesterol Ratio ............................................................................................................................................... 11
LDL Cholesterol ................................................................................................................................................. 13
Triglycerides ....................................................................................................................................................... 15
Blood Glucose ........................................................................................................................................................ 17
Fasting Plasma Glucose Test (FPG).............................................................................................................. 17
Non-Fasting Plasma Glucose Test (NFPG) ................................................................................................. 19
Hemoglobin A1c ................................................................................................................................................ 21
LIPID PANEL AND GYLYCEMIC SUMMARY ..................................................................................................... 23
BIOMETRIC SCREENING RESULTS ................................................................................................................... 24
Blood Pressure ....................................................................................................................................................... 25
Systolic ................................................................................................................................................................ 25
Diastolic .............................................................................................................................................................. 27
Resting Pulse ......................................................................................................................................................... 30
Body Composition.................................................................................................................................................. 32
Body Mass Index (BMI) .................................................................................................................................... 32
Waist Circumference......................................................................................................................................... 34
Waist-Hip Ratio (WHR)..................................................................................................................................... 38
Percent Body Fat ............................................................................................................................................... 41
Bone Mineral Density (T-Score) .......................................................................................................................... 45
BIOMETRICS SCREENING SUMMARY ............................................................................................................... 47
PULMONARY ASSESSMENT ................................................................................................................................ 50
Lung Function ......................................................................................................................................................... 51
Forced Vital Capacity (FVC) ............................................................................................................................ 51
Peak Expiratory Flow Rate (PEFR) ................................................................................................................ 52
Chronic Obstructive Pulmonary Disease (COPD) Risk Assessment ........................................................ 53
Lung Age Assessment ...................................................................................................................................... 54
Smoking .................................................................................................................................................................. 54
HEALTHY PEOPLE 2010 ........................................................................................................................................ 56
METABOLIC SYNDROME ...................................................................................................................................... 59
CRITICAL VALUE STATISTICS ............................................................................................................................. 60
DISCUSSION ............................................................................................................................................................. 61
WHAT TO DO NEXT ................................................................................................................................................. 63
REFERENCES ........................................................................................................................................................... 64
Page 2 of 64
INTRODUCTION
Summit Health is pleased to provide {Company Name} with their {Screening Name} results that
took place between {Date} and {Date}. This is the {1st, 2nd, 3rd, etc.} time {Company Name} has
completed health screening with Summit Health. This aggregate report summarizes the group
results for employees that participated in the screening. Tables in this report can provide up to
five years of comparison data. If {Company Name} has completed more than five years of
screenings with Summit Health, data from the five most recent screenings will appear in this
report.
The results presented in this report are a snapshot of participants’ overall health based on
biometric screening tests only, and should not be construed as diagnostic. Depending on fasting
status, employees were offered some or all of the following biometric screening tests:
ƒ Total Cholesterol (TC)
ƒ High Density Lipoprotein (HDL) – Good Cholesterol
ƒ TC/HDL Ratio (Coronary Risk Ratio)
ƒ Low Density Lipoprotein (LDL) – Bad Cholesterol
ƒ Triglycerides
ƒ Blood Glucose
ƒ Blood Pressure
ƒ Height & Weight
ƒ Body Mass Index (BMI)
Participants received written results at the conclusion of the screening and consulted “one-onone” with a healthcare professional. When appropriate, lifestyle changes were discussed with
employees to help reduce their cardiovascular risk and lead healthier lives.
Summit Health complies with HIPPA Privacy and Security Standards and maintains the
confidentiality of all health screening participants. Individual test results are never released unless
written consent is obtained from the participant. All participants signed an Informed Consent and
were given the opportunity to review Summit Health’s Notice of Privacy Practices that explains
the testing procedures and potential risk involved in participation. Employees had the option of
participating in any or all biometric screening tests.
Table 1. Screening Schedule
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Location
{Location 1}
{Date}
{Date}
{Date}
{Date}
{Date}
{Location 2}
{Date}
{Date}
{Date}
{Date}
{Date}
{Location 3}
{Date}
{Date}
{Date}
{Date}
{Date}
{Location 4}
{Date}
{Date}
{Date}
{Date}
{Date}
{Location 5}
{Date}
{Date}
{Date}
{Date}
{Date}
{Location 6}
{Date}
{Date}
{Date}
{Date}
{Date}
{Location 7}
{Date}
{Date}
{Date}
{Date}
{Date}
{Location 8}
{Date}
{Date}
{Date}
{Date}
{Date}
{Page break here}
Page 3 of 64
PARTICIPANT DEMOGRAPHICS
Across all locations, {number} employees participated in the most recent screening. Site
participation is provided in Table 2. The average age of male participants was {#}, and {#} for
females. Average age of all participants was {#}. A breakdown of participation by gender and age
is provided in Table 3.
Table 2. Participation by Location
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
Location
{Location 1}
{Location 2}
{Location 3}
{Location 4}
{Location 5}
{Location 6}
{Location 7}
{Location 8}
Company Total
{Date} to {date}
{Date} to {date}
{Date} to {date}
{Date} to {date}
{Date} to {date}
Participants
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{Total}
Participants
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{Total}
Participants
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{Total}
Participants
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{Total}
Participants
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{Total}
Table 3. Participation by Gender and Age
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
Female*
Male
Gender
Age
< 21
22-29
30-39
40-49
50-59
60+
< 21
22-29
30-39
40-49
50-59
60+
Total
{Date} to {date}
{Date} to {date}
{Date} to {date}
{Date} to {date}
{Date} to {date}
Participation
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{Total}
Participation
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{Total}
Participation
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{Total}
Participation
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{Total}
Participation
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{Total}
* Pregnant women are included in age/gender count, but are excluded from stratification in the Body Composition
section of this report.
{Page break here}
Page 4 of 64
{COMPANY NAME}
LIPID PANEL AND GYLYCEMIC RESULTS
{Page break here}
Page 5 of 64
Cholesterol
Cholesterol is a soft, waxy substance found in the bloodstream and the body’s cells. The body
needs cholesterol to form cell membranes, hormones, and even some vitamins. However, when
cholesterol levels are elevated, there is increased risk for heart attack and stroke. Depending on
fasting status, participants were screened on some or all of following blood lipid components:
ƒ
ƒ
ƒ
ƒ
ƒ
Total Cholesterol (TC)
High Density Lipoprotein (HDL)
TC/HDL Ratio (Coronary Risk Ratio)
Low Density Lipoprotein (LDL)
Triglycerides
Total Cholesterol
Total Cholesterol (TC) should be taken into account when evaluating cardiovascular risk.
According to the National Cholesterol Education Program, ‘desirable’ TC is less than 200 mg/dL.
Total Cholesterol levels from 200-239 mg/dL are considered ‘borderline high,’ and levels of 240
mg/dL or greater are considered ‘high risk.’ Individuals with TC levels in the ‘borderline high’ and
‘high risk’ ranges are twice as likely to develop coronary heart disease as those with levels below
200 mg/dL.1, 2, 3
Table 4. TC Risk Stratification – Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 200 mg/dL
{#}
{#}
{#}
{#}
{#}
Desirable
200 – 239 mg/dL
{#}
{#}
{#}
{#}
{#}
Borderline High
≥ 240 mg/dL
{#}
{#}
{#}
{#}
{#}
High Risk
Total
{%}
{%}
{%}
{%}
{%}
Table 5. TC Risk Stratification Percent
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 200 mg/dL
{%}
{%}
{%}
{%}
{%}
Desirable
200 – 239 mg/dL
{%}
{%}
{%}
{%}
{%}
Borderline High
≥ 240 mg/dL
{%}
{%}
{%}
{%}
{%}
High Risk
Total
{%}
{%}
{%}
{%}
{%}
{Page break here}
Page 6 of 64
The average Total Cholesterol for {Company Name} employees is {Number} mg/dL. The
national average is 199 mg/dL for Americans aged 20 to 74 years. Approximately 15.7% of
Americans aged 20 to 74 have high cholesterol (greater than 240 mg/dL).4
Graph 1. Average TC for {Company Name}
199
U.S. Average
<200
Desirable
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
0
50
100
150
200
250
300
Graph 2. Average TC by Location
{Location 1}
{#}
{#}
{Location 2}
{Location 3}
{#}
{Location 4}
{#}
{Location 5}
{#}
{Location 6}
{#}
{Location 7}
{#}
{Location 8}
{#}
{Location 9}
{#}
{Location 10}
{#}
0
50
100
150
200
250
{Page break here}
Page 7 of 64
HDL Cholesterol
High Density Lipoprotein (HDL) is called “Good Cholesterol” because it transports cholesterol
from blood vessels and body tissue back to the liver for excretion or reutilization. HDL values of
greater than 60 mg/dL are ‘desirable’ and believed to decrease the risk for heart disease. HDL
values less than 40 mg/dL for men, and 50 mg/dL for women, may significantly increase an
individual’s risk for heart disease.1, 3 Approximately {#}% of employees screened have ’High Risk’
levels of HDL cholesterol.
Table 6. Male HDL Risk Stratification – Frequency
Screening {#}
Screening {#}
Screening {#}
Screening {#}
Screening {#}
Risk Category
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
> 60 mg/dL
{#}
{#}
{#}
{#}
{#}
Desirable
40 – 60 mg/dL
{#}
{#}
{#}
{#}
{#}
Moderate Risk
< 40 mg/dL
{#}
{#}
{#}
{#}
{#}
High Risk
Total
{#}
{#}
{#}
{#}
{#}
Table 7. Male HDL Risk Stratification – Percent
Screening {#}
Screening {#}
Screening {#}
Screening {#}
Screening {#}
Risk Category
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
> 60 mg/dL
{%}
{%}
{%}
{%}
{%}
Desirable
40 – 60 mg/dL
{%}
{%}
{%}
{%}
{%}
Moderate Risk
< 40 mg/dL
{%}
{%}
{%}
{%}
{%}
High Risk
Total
{%}
{%}
{%}
{%}
{%}
Table 8. Female HDL Risk Stratification – Frequency
Screening {#}
Screening {#}
Screening {#}
Screening {#}
Screening {#}
Risk Category
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
> 60 mg/dL
{#}
{#}
{#}
{#}
{#}
Desirable
50 – 60 mg/dL
{#}
{#}
{#}
{#}
{#}
Moderate Risk
< 50 mg/dL
{#}
{#}
{#}
{#}
{#}
High Risk
Total
{#}
{#}
{#}
{#}
{#}
Table 9. Female HDL Risk Stratification – Percent
Screening {#}
Screening {#}
Screening {#}
Screening {#}
Screening {#}
Risk Category
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
> 60 mg/dL
{%}
{%}
{%}
{%}
{%}
Desirable
50 – 60 mg/dL
{%}
{%}
{%}
{%}
{%}
Moderate Risk
< 50 mg/dL
{%}
{%}
{%}
{%}
{%}
High Risk
Total
{%}
{%}
{%}
{%}
{%}
{Page break here}
Page 8 of 64
According to the American Heart Association, the average HDL value for American males ranges
from 40-50 mg/dL and the average for females ranges from 50-60 mg/dL.2 The average HDL
value for male {Company Name} employees is {#} mg/dL, and {#} mg/dL for female employees.
Graph 3. Male Average HDL for {Company Name}
U.S. Average
40-50
Desirable
>60
Screening {#}
{#}
Screening {#}
{#}
{#}
Screening {#}
Screening {#}
{#}
{#}
Screening {#}
0
10
20
30
40
50
60
70
Graph 4. Male Average HDL by Location
{Location 1}
{#}
{#}
{Location 2}
{Location 3}
{#}
{Location 4}
{#}
{Location 5}
{#}
{Location 6}
{#}
{#}
{Location 7}
{Location 8}
{#}
{Location 9}
{#}
{Location 10}
{#}
0
10
20
30
40
50
60
70
80
{Page break here}
Page 9 of 64
Graph 5. Female Average HDL for {Company Name}
U.S. Average
50-60
Desirable
>60
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
0
10
20
30
40
50
60
70
Graph 6. Female Average HDL by Location
{Location 1}
{#}
{Location 2}
{#}
{Location 3}
{#}
{Location 4}
{#}
{Location 5}
{#}
{Location 6}
{#}
{Location 7}
{#}
{Location 8}
{#}
{Location 9}
{#}
{Location 10}
{#}
0
10
20
30
40
50
60
70
80
{Page break here}
Page 10 of 64
Cholesterol Ratio (Coronary Risk Ratio)
Total Cholesterol/High Density Lipoprotein (TC/HDL) Ratio is the relationship between Total and
HDL cholesterol. The TC/HDL Ratio is important when determining a person’s risk for heart
disease. A lower ratio means lower risk. Ideally, this should result from a low Total Cholesterol
and a high HDL value. A ratio below 5.0 is ‘desirable,’ while 3.5 and below is ‘optimal.’5
Table 10. TC/HDL Ratio Risk Stratification – Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 3.5 mg/dL
{#}
{#}
{#}
{#}
{#}
Optimal
3.5 – 5.0 mg/dL
{#}
{#}
{#}
{#}
{#}
Desirable
> 5.0 mg/dL
{#}
{#}
{#}
{#}
{#}
Increased Risk
Total
{#}
{#}
{#}
{#}
{#}
Table 11. TC/HDL Ratio Risk Stratification – Percent
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 3.5 mg/dL
{%}
{%}
{%}
{%}
{%}
Optimal
3.5 – 5.0 mg/dL
{%}
{%}
{%}
{%}
{%}
Desirable
> 5.0 mg/dL
{%}
{%}
{%}
{%}
{%}
Increased Risk
Total
{%}
{%}
{%}
{%}
{%}
{Page break here}
Page 11 of 64
The average TC/HDL Ratio for {Company Name} employees is {#} mg/dL.
Graph 7. Average TC/HDL Ratio for {Company Name}
Optimal
<3.5
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
0.0
1.0
2.0
3.0
4.0
5.0
6.0
Graph 8. Average TC/HDL Ratio by Location
{Location 1}
{#}
{#}
{Location 2}
{Location 3}
{#}
{Location 4}
{#}
{Location 5}
{#}
{Location 6}
{#}
{#}
{Location 7}
{Location 8}
{#}
{Location 9}
{#}
{Location 10}
{#}
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
{Page break here}
Page 12 of 64
LDL Cholesterol
Low Density Lipoprotein (LDL) is called “Bad Cholesterol” because it transports cholesterol to
organs, tissue, and arteries where it can be deposited on vessel walls in the form of plaque.
Individual risk factors (smoking, high blood pressure, low HDL, family history of cardiovascular
disease, gender and age) can affect LDL levels and must be taken into account when interpreting
results. LDL levels less than 100 mg/dL are ‘optimal,’ while values from 100 to 129 mg/dL are
’near optimal/above optimal.’ Values from 130 to 159 are considered ‘borderline high.’ A value
within the range of 160 to 189 is considered ‘high,’ and above 189 is considered ‘very high.’1, 2, 3
Table 12. LDL Risk Stratification – Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 100 mg/dL
{#}
{#}
{#}
{#}
{#}
Optimal
100 – 129 mg/dL
{#}
{#}
{#}
{#}
{#}
Near / Above Optimal
130 – 159 mg/dL
Borderline High
160 – 189 mg/dL
High
≥ 190 mg/dL
Very High
Total
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
Table 13. LDL Risk Stratification – Percent
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 100 mg/dL
{%}
{%}
{%}
{%}
{%}
Optimal
100 – 129 mg/dL
{%}
{%}
{%}
{%}
{%}
Near / Above Optimal
130 – 159 mg/dL
Borderline High
160 – 189 mg/dL
High
≥ 190 mg/dL
Very High
Total
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{Page break here}
Page 13 of 64
The average LDL level for {Company Name} employees is {#} mg/dL, which falls within the
{Optimal, Near/Above Optimal, Borderline High, High, or Very High} Risk category.
Graph 9. Average LDL for {Company Name}
Optimal
<100
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
0
20
40
60
80
100
120
140
Graph 10. Average LDL by Location
{Location 1}
{#}
{Location 2}
{#}
{Location 3}
{#}
{Location 4}
{#}
{Location 5}
{#}
{Location 6}
{#}
{Location 7}
{#}
{Location 8}
{#}
{Location 9}
{#}
{Location 10}
{#}
95
100
105
110
115
120
125
130
135
{Page break here}
Page 14 of 64
Triglycerides
Triglycerides are a type of fat that provides cells with energy to function. However, elevated levels
may increase the risk of atherosclerosis (hardening of the arteries), heart disease, and stroke.
Triglycerides levels below 150 mg/dL are considered ‘normal,’ while levels from 150-199 are
considered ‘borderline high.’ Values from 200-499 are categorized as ‘high,’ and values above
499 mg/dL are considered ‘very high’ and place individuals at significant risk for cardiovascular
disease.1, 3
Table 14. Triglyceride Risk Stratification – Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 150 mg/dL
{#}
{#}
{#}
{#}
{#}
Normal
150 – 199 mg/dL
{#}
{#}
{#}
{#}
{#}
Borderline High
200 – 499 mg/dL
{#}
{#}
{#}
{#}
{#}
High
≥ 500 mg/dL
{#}
{#}
{#}
{#}
{#}
Very High
Total
{#}
{#}
{#}
{#}
{#}
Table 15. Triglyceride Risk – Percent
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 150 mg/dL
{%}
{%}
{%}
{%}
{%}
Normal
150 – 199 mg/dL
{%}
{%}
{%}
{%}
{%}
Borderline High
200 – 499 mg/dL
{%}
{%}
{%}
{%}
{%}
High
≥ 500 mg/dL
{%}
{%}
{%}
{%}
{%}
Very High
Total
{%}
{%}
{%}
{%}
{%}
{Page break here}
Page 15 of 64
The average Triglycerides value for {Company Name} employees is {#} mg/dL.
Graph 11. Average Triglycerides for {Company Name}
Normal
<150
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
0
20
40
60
80
100
120
140
160
Graph 12. Average Triglycerides by Location
{Location 1}
{#}
{Location 2}
{#}
{Location 3}
{#}
{Location 4}
{#}
{Location 5}
{#}
{Location 6}
{#}
{Location 7}
{#}
{Location 8}
{#}
{Location 9}
{#}
{Location 10}
110
{#}
115
120
125
130
135
140
{Page break here}
Page 16 of 64
Blood Glucose
Glucose is the main sugar in the blood that provides energy needed to perform everyday
activities. Elevated or uncontrolled glucose levels can lead to diabetes, a condition in which the
body does not produce or properly use insulin. If uncontrolled, diabetes may lead to heart, eye,
kidney, or nerve damage. There are two primary types of diabetes. Type 1 diabetes involves a
complete breakdown of the insulin production in the body. This type of diabetes is usually
diagnosed before the age of 25 and requires insulin injections or an insulin pump. Type 2
diabetes is the most common form of the disease. This occurs when the body cannot produce
and use its own insulin well enough to control blood glucose (sugar) levels. Typically, changes in
lifestyle can prevent or help reverse Type 2 diabetes. According to the American Diabetes
Association 23.6 million adults Americans (children and adults) have diabetes, and approximately
one-quarter of them do not even know it.6 Diabetes is indicated by a fasting blood glucose level
greater than 125 mg/dL or non-fasting levels over 199 mg/dL.7 Approximately 57 million
Americans are estimated to have “pre-diabetes,” characterized by fasting glucose values of 100
to 125 mg/dL or non-fasting glucose values of 140 to 199.6, 7 The American Diabetes Association
suggests ‘normal’ values for fasting glucose are below 100 mg/dL and less than 140 for nonfasting glucose.7
Fasting Plasma Glucose Test (FPG)
Table 16. Fasting Glucose Risk Stratification – Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 100 mg/dL
{#}
{#}
{#}
{#}
{#}
Normal
100 – 125 mg/dL
{#}
{#}
{#}
{#}
{#}
Pre-Diabetes
> 125 mg/dL
{#}
{#}
{#}
{#}
{#}
Diabetic Indication
Total
{#}
{#}
{#}
{#}
{#}
Table 17. Fasting Glucose Risk Stratification – Percent
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 100 mg/dL
{%}
{%}
{%}
{%}
{%}
Normal
100 – 125 mg/dL
{%}
{%}
{%}
{%}
{%}
Pre-Diabetes
> 125 mg/dL
{%}
{%}
{%}
{%}
{%}
Diabetic Indication
Total
{%}
{%}
{%}
{%}
{%}
{Page break here}
Page 17 of 64
The average fasting glucose level for {Company Name} employees is {#} mg/dL. The cutoff for
the ‘normal’ range is 99 mg/dL.
Graph 13. Average Fasting Glucose for {Company Name}
'Normal'
<100
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
0
20
40
60
80
100
120
140
Graph 14. Average Fasting Glucose by Location
{Location 1}
{#}
{Location 2}
{#}
{Location 3}
{#}
{Location 4}
{#}
{Location 5}
{#}
{Location 6}
{#}
{Location 7}
{#}
{Location 8}
{#}
{Location 9}
{#}
{Location 10}
{#}
0
20
40
60
80
100
120
140
{Page break here}
Page 18 of 64
Non-Fasting Plasma Glucose Test (NFPG)
Table 18. Non-Fasting Glucose Risk Stratification – Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 140 mg/dL
{#}
{#}
{#}
{#}
{#}
Normal
140 – 199 mg/dL
{#}
{#}
{#}
{#}
{#}
Pre-Diabetes
> 199 mg/dL
{#}
{#}
{#}
{#}
{#}
Diabetic Indication
Total
{#}
{#}
{#}
{#}
{#}
Table 19. Non-Fasting Glucose Risk Stratification – Percent
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 140 mg/dL
{%}
{%}
{%}
{%}
{%}
Normal
140 – 199 mg/dL
{%}
{%}
{%}
{%}
{%}
Pre-Diabetes
> 199 mg/dL
{%}
{%}
{%}
{%}
{%}
Diabetic Indication
Total
{%}
{%}
{%}
{%}
{%}
{Page break here}
Page 19 of 64
The average non-fasting glucose level for {Company Name} employees is {#} mg/dL. The cutoff
for the ‘normal’ range is 139 mg/dL.
Graph 15. Average Non-Fasting Glucose for {Company Name}
'Normal'
<140
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
0
50
100
150
200
250
Graph 16. Average Non-Fasting Glucose by Location
{Location 1}
{#}
{Location 2}
{#}
{Location 3}
{#}
{Location 4}
{#}
{Location 5}
{#}
{Location 6}
{#}
{Location 7}
{#}
{Location 8}
{#}
{Location 9}
{#}
{Location 10}
{#}
0
50
100
150
200
250
{Page break here}
Page 20 of 64
Hemoglobin A1c
The A1c test (also known as glycated hemoglobin or HbA1c) is used to monitor blood sugar
control of people with diabetes, with the goal of keeping their levels as close to ‘normal’ as
possible to help minimize complications associated with elevated glucose. Hemoglobin A1c tells
the average amount of glucose in the blood over a six to twelve-week period. The American
Diabetes Association suggests a ‘normal’ hemoglobin A1c is less than 7% for people with
diabetes.8 It is recommended that people with diabetes have a hemoglobin A1c less than 7%
because a higher hemoglobin A1c is associated with elevated risk of complications.
Table 20. Hemoglobin A1c Risk Stratification – Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 7%
{#}
{#}
{#}
{#}
{#}
Normal
7% +
{#}
{#}
{#}
{#}
{#}
Elevated Risk
Total
{#}
{#}
{#}
{#}
{#}
Table 21. Hemoglobin A1c Risk Stratification – Percent
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
<7%
{%}
{%}
{%}
{%}
{%}
Normal
7% +
{%}
{%}
{%}
{%}
{%}
Elevated Risk
Total
{%}
{%}
{%}
{%}
{%}
{Page break here}
Page 21 of 64
Graph 17. Average Hemoglobin A1c for {Company Name}
'Normal'
<7.0%
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
0.0%
{#}
1.0%
2.0%
3.0%
4.0%
5.0%
6.0%
7.0%
8.0%
Graph 18. Average Hemoglobin A1c by Location
{Location 1}
{#}
{Location 2}
{#}
{Location 3}
{#}
{Location 4}
{#}
{Location 5}
{#}
{Location 6}
{#}
{Location 7}
{#}
{Location 8}
{#}
{Location 9}
{#}
{Location 10}
0.0%
{#}
2.0%
4.0%
6.0%
8.0%
10.0%
{Page break here}
Page 22 of 64
LIPID PANEL AND GYLYCEMIC SUMMARY
The tables below provide a summary of the risk stratification for the lipid panel and glycemic
testing results conducted at {Company Name} on {date(s)}.
Table 22. Section Summary – Lipid Panel and Glycemic Testing – Frequency
Risk
Low Risk/Desirable
Moderate Risk/Borderline
High Risk
Category
Total
< 200
200 – 240
> 240
{#}
{#}
Cholesterol
mg/dL
mg/dL
mg/dL
40 – 60 mg/dL –
< 40 mg/dL –
HDL
> 60
Males
Males
{#}
{#}
50 – 60 mg/dL < 50 mg/dL –
Cholesterol
mg/dL
Females
Females
Cholesterol
< 3.5
3.5 – 5.0
> 5.0
{#}
{#}
Ratio
mg/dL
mg/dL
mg/dL
LDL
< 100
100 – 159
> 159
{#}
{#}
Cholesterol
mg/dL
mg/dL
mg/dL
< 150
150 – 199
≥ 200
Triglycerides
{#}
{#}
mg/dL
mg/dL
mg/dL
Fasting
< 100
100 – 125
> 125
{#}
{#}
Glucose
mg/dL
mg/dL
mg/dL
Non-Fasting
< 140
140-199
> 199
{#}
{#}
Glucose
mg/dL
mg/dL
mg/dL
Hemoglobin
>7%
{#}
7% +
A1c
Total
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
Table 23. Section Summary – Lipid Panel and Glycemic Testing – Percent
Risk
Low Risk/Desirable
Moderate Risk/Borderline
High Risk
Category
Total
< 200
200 – 240
> 240
{%}
{%}
{%}
Cholesterol
mg/dL
mg/dL
mg/dL
40 – 60 mg/dL –
< 40 mg/dL –
HDL
> 60
Males
Males
{%}
{%}
{%}
50 – 60 mg/dL < 50 mg/dL Cholesterol
mg/dL
Females
Females
Cholesterol
< 3.5
3.5 – 5.0
> 5.0
{%}
{%}
{%}
Ratio
mg/dL
mg/dL
mg/dL
LDL
< 100
100 – 159
> 159
{%}
{%}
{%}
Cholesterol
mg/dL
mg/dL
mg/dL
< 150
150 – 199
≥ 200
Triglycerides
{%}
{%}
{%}
mg/dL
mg/dL
mg/dL
Fasting
< 100
100 – 125
> 125
{%}
{%}
{%}
Glucose
mg/dL
mg/dL
mg/dL
Non-Fasting
< 140
140-199
> 199
{%}
{%}
{%}
Glucose
mg/dL
mg/dL
mg/dL
Hemoglobin
>7%
{%}
7% +
{%}
A1c
Total
{%}
{%}
{%}
{Page break here}
Page 23 of 64
{COMPANY NAME}
BIOMETRIC SCREENING RESULTS
{Page break here}
Page 24 of 64
Blood Pressure
Blood pressure is the force blood exerts on artery walls when the heart contracts (systolic – top
number) and relaxes (diastolic – bottom number). As blood pressure increases, so does the risk
for heart disease, kidney disease, stroke, eye damage, and hardening of the arteries
(arthrosclerosis). Hypertension is chronically elevated blood pressure. Hypertension is commonly
referred to as the “Silent Killer” because it typically produces no symptoms. According to the
National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure
(JNC-7) ‘normal’ blood pressure consists of a systolic reading of <120 and a diastolic reading of
< 80 mmHg. A systolic reading of 120-139 or a diastolic reading of 80-89 places an individual in
the ‘pre-hypertension’ category. Individuals with a systolic reading of 140-159 or a diastolic
reading of 90-99 are categorized as having ‘hypertension, stage-1,’ and those with a systolic
reading great than 159 or a diastolic reading greater than 99 are categorized as having
‘hypertension, stage-2.’ 9
Systolic
Table 24. Systolic Blood Pressure Risk Stratification – Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 120 mmHg
{#}
{#}
{#}
{#}
{#}
Normal
120 – 139 mmHg
{#}
{#}
{#}
{#}
{#}
Pre-Hypertensive
140 – 159 mmHg
{#}
{#}
{#}
{#}
{#}
Stage 1 Hypertension
160 + mmHg
{#}
{#}
{#}
{#}
{#}
Stage 2 Hypertension
Total
{#}
{#}
{#}
{#}
{#}
Table 25. Systolic Blood Pressure Risk Stratification – Percent
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 120 mmHg
{%}
{%}
{%}
{%}
{%}
Normal
120 – 139 mmHg
{%}
{%}
{%}
{%}
{%}
Pre-Hypertensive
140 – 159 mmHg
{%}
{%}
{%}
{%}
{%}
Stage 1 Hypertension
160 + mmHg
{%}
{%}
{%}
{%}
{%}
Stage 2 Hypertension
Total
{%}
{%}
{%}
{%}
{%}
{Page break here}
Page 25 of 64
The average systolic blood pressure for {Company Name} employees is {#} mm/Hg. The cutoff
for the ‘normal’ range is 119 mmHg.
Graph 19. Average Systolic Blood Pressure for {Company Name}
<120
'Normal'
Screening {#}
{#}
{#}
Screening {#}
Screening {#}
{#}
{#}
Screening {#}
{#}
Screening {#}
0
20
40
60
80
100
120
140
160
180
Graph 20. Average Systolic Blood Pressure by Location
{Location 1}
{#}
{#}
{Location 2}
{Location 3}
{#}
{Location 4}
{#}
{Location 5}
{#}
{Location 6}
{#}
{#}
{Location 7}
{Location 8}
{#}
{Location 9}
{#}
{Location 10}
105
{#}
110
115
120
125
130
135
{Page break here}
Page 26 of 64
Diastolic
Table 26. Diastolic Blood Pressure Risk Stratification – Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 80 mmHg
{#}
{#}
{#}
{#}
{#}
Normal
80 – 89 mmHg
{#}
{#}
{#}
{#}
{#}
Pre-Hypertensive
90 – 99 mmHg
{#}
{#}
{#}
{#}
{#}
Stage 1 Hypertension
100 + mmHg
{#}
{#}
{#}
{#}
{#}
Stage 2 Hypertension
Total
{#}
{#}
{#}
{#}
{#}
Table 27. Diastolic Blood Pressure Risk Stratification – Percent
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 80 mmHg
{%}
{%}
{%}
{%}
{%}
Normal
80 – 89 mmHg
{%}
{%}
{%}
{%}
{%}
Pre-Hypertensive
90 – 99 mmHg
{%}
{%}
{%}
{%}
{%}
Stage 1 Hypertension
100 + mmHg
{%}
{%}
{%}
{%}
{%}
Stage 2 Hypertension
Total
{%}
{%}
{%}
{%}
{%}
{Page break here}
Page 27 of 64
The average diastolic blood pressure for {Company Name} employees is {#} mm/Hg. The cutoff
for the ‘normal’ range is 79 mmHg.
Graph 21. Average Diastolic Blood Pressure for {Company Name}
<80
'Normal'
Screening {#}
{#}
{#}
Screening {#}
Screening {#}
{#}
{#}
Screening {#}
{#}
Screening {#}
0
20
40
60
80
100
120
Graph 22. Average Diastolic Blood Pressure by Location
{Location 1}
{#}
{#}
{Location 2}
{Location 3}
{#}
{Location 4}
{#}
{Location 5}
{#}
{Location 6}
{#}
{Location 7}
{#}
{Location 8}
{#}
{Location 9}
{#}
{Location 10}
{#}
0
20
40
60
80
100
{Page break here}
Page 28 of 64
Table 28. Overall Blood Pressure Risk Stratification – Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
Risk Category
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Normal
Systolic: <120 mmHg
{#}
{#}
{#}
{#}
{#}
AND
Diastolic: <80 mmHg
Pre-Hypertensive
Systolic: 120–139 mmHg
{#}
{#}
{#}
{#}
{#}
OR
Diastolic: 80–89 mmHg
Hypertension, Stage-1
Systolic: 140–159 mmHg
{#}
{#}
{#}
{#}
{#}
OR
Diastolic: 90–99 mmHg
Hypertension, Stage-2
Systolic: 160+ mmHg
{#}
{#}
{#}
{#}
{#}
OR
Diastolic: 90+ mmHg
Total
{#}
{#}
{#}
{#}
{#}
Table 29. Overall Blood Pressure Risk Stratification – Percent
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
Risk Category
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Normal
Systolic: <120 mmHg
{%}
{%}
{%}
{%}
{%}
AND
Diastolic: <80 mmHg
Pre-Hypertensive
Systolic: 120–139 mmHg
{%}
{%}
{%}
{%}
{%}
OR
Diastolic: 80–89 mmHg
Hypertension, Stage-1
Systolic: 140–159 mmHg
{%}
{%}
{%}
{%}
{%}
OR
Diastolic: 90–99 mmHg
Hypertension, Stage-2
Systolic: 160+ mmHg
{%}
{%}
{%}
{%}
{%}
OR
Diastolic: 90+ mmHg
Total
{%}
{%}
{%}
{%}
{%}
Page 29 of 64
Resting Pulse
Pulse rate is also referred to as heart rate, and is the number of times a person’s heart beats
each minute. Normal range for people over age 17 is 60 - 100 beats per minute (bpm). It is not
unusual for a well conditioned athlete to have a resting heart rate between 40 – 59 bpm.10 A
slower heart rate than normal may be caused by one or more of the following: heart disease,
heart medication, high levels of fitness, and/or an under-active thyroid gland (hypothyroidism). A
faster heart rate may be caused by one or more of the following: activity or exercise, anemia,
decongestants, fever, heart disease, an overactive thyroid gland (hyperthyroidism), medication
used to treat asthma, stimulants such as caffeine, amphetamines, diet pills, and cigarettes,
drinking alcohol, and/or stress.
Table 30. Resting Pulse – Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Resting Pulse
40 – 59 bpm
{#}
{#}
{#}
{#}
{#}
60 – 100 bpm
{#}
{#}
{#}
{#}
{#}
> 100 bpm
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
Total
Table 31. Resting Pulse – Percent
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Resting Pulse
40 – 59 bpm
{%}
{%}
{%}
{%}
{%}
60 – 100 bpm
{%}
{%}
{%}
{%}
{%}
> 100 bpm
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
Total
{Page break here}
Page 30 of 64
Graph 23. Average Resting Pulse for {Company Name}
≤100
'Normal'
Screening {#}
{#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
0
20
40
60
80
100
120
Graph 24. Average Resting Pulse by Location
{Location 1}
{#}
{#}
{Location 2}
{Location 3}
{#}
{Location 4}
{#}
{Location 5}
{#}
{Location 6}
{#}
{Location 7}
{#}
{Location 8}
{#}
{Location 9}
{#}
{Location 10}
{#}
0
20
40
60
80
100
{Page break here}
Page 31 of 64
Body Composition
Body composition is recognized as an important risk factor associated with coronary heart
disease and diabetes. Body mass index (BMI) is one of the easiest methods for assessing
overweight and obesity at the population level. However, because the calculation requires only
height and weight, it may not accurately assess body composition among individuals with
significant muscle mass. For adults aged 20 years and older, BMI is interpreted using standard
weight status categories that are the same for men and women. According to the U.S. Centers for
Disease Control and Prevention, Body Mass Index correlates significantly with many chronic
health conditions, including hypertension, hyperlipidemia, Type 2 diabetes, coronary heart
disease, cardiovascular accidents or stroke, gallbladder dysfunction, osteoarthritis, sleep apnea
and respiratory problems, some cancers (e.g., endometrial, breast, colon) and chronic pain
disorders.11 In addition to smoking cessation, weight reduction is one of the most effective ways
to improve a population’s health risk status.
Pregnant females are excluded from all body composition screening results.
Body Mass Index (BMI)
Table 32. BMI Risk Stratification – Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category12
< 18.5
Underweight
18.5 – 24.9
Normal
25 – 29.9
Overweight
30.0– 34.9
Obesity Class I
35.0 – 39.9
Obesity Class II
40.0 +
Obesity Class III
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
{#}
Table 33. BMI Risk Stratification – Percent
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 18.5
Underweight
18.5 – 24.9
Normal
25 – 29.9
Overweight
30.0– 34.9
Obesity Class I
35.0 – 39.9
Obesity Class II
40.0 +
Obesity Class III
Total
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{%}
{Page break here}
Page 32 of 64
The average Body Mass Index for {Company Name} employees is {#}. The ‘normal’ cutoff for
BMI is 24.9.
Graph 25. Average BMI for {Company Name}
'Normal'
<25.0
Screening {#}
{#}
Screening {#}
{#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
Graph 26. Average BMI by Location
{Location 1}
{#}
{Location 2}
{#}
{Location 3}
{#}
{Location 4}
{#}
{Location 5}
{#}
{Location 6}
{#}
{Location 7}
{#}
{Location 8}
{#}
{Location 9}
{#}
{Location 10}
{#}
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
{Page break here}
Page 33 of 64
Waist Circumference
A high waist circumference (indicating a high amount of abdominal fat) is associated with
increased risk for hypertension, type 2 diabetes, high cholesterol, and heart disease. The
measurement is taken by using a cloth tape measure or string held at the hip bone, and wrapping
it around the abdomen, so that it is up against the skin without compressing it, at the narrowest
part (usually at or just above the level of the navel) The individual being measured should stand
with a straight and relaxed posture, arms hanging by their side. They should breathe normally
and not hold their breath or hold in their stomach. To avoid increased risk, males should have a
waist circumference of 99 cm or less, and 89 cm or less for females.12
Table 34. Male Waist Circumference Risk Stratification – Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 80 cm
{#}
{#}
{#}
{#}
{#}
Very Low
80 – 99 cm
{#}
{#}
{#}
{#}
{#}
Low
100 – 120 cm
{#}
{#}
{#}
{#}
{#}
High
> 120 cm
{#}
{#}
{#}
{#}
{#}
Very High
Total
{#}
{#}
{#}
{#}
{#}
Table 35. Male Waist Circumference Risk Stratification – Percent
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 80 cm
{%}
{%}
{%}
{%}
{%}
Very Low
80 – 99 cm
{%}
{%}
{%}
{%}
{%}
Low
100 – 120 cm
{%}
{%}
{%}
{%}
{%}
High
> 120 cm
{%}
{%}
{%}
{%}
{%}
Very High
Total
{%}
{%}
{%}
{%}
{%}
Page 34 of 64
Table 36. Female Waist Circumference Risk Stratification – Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 70 cm
{#}
{#}
{#}
{#}
{#}
Very Low
70 – 89 cm
{#}
{#}
{#}
{#}
{#}
Low
90 – 109 cm
{#}
{#}
{#}
{#}
{#}
High
> 110 cm
{#}
{#}
{#}
{#}
{#}
Very High
Total
{#}
{#}
{#}
{#}
{#}
Table 37. Female Waist Circumference Risk Stratification – Percent
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 70 cm
{%}
{%}
{%}
{%}
{%}
Very Low
70 – 89 cm
{%}
{%}
{%}
{%}
{%}
Low
90 – 109 cm
{%}
{%}
{%}
{%}
{%}
High
> 110 cm
{%}
{%}
{%}
{%}
{%}
Very High
Total
{%}
{%}
{%}
{%}
{%}
{Page break here}
Page 35 of 64
The average waist circumference for male {Company Name} employees is {#} cm. The ‘low’
cutoff is 99 cm for males.
Graph 27. Average Male Waist Circumference for {Company Name}
<100
'Low'
{#}
Screening {#}
{#}
Screening {#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
0
20
40
60
80
100
120
Graph 28. Average Male Waist Circumference by Location
{#}
{Location 1}
{#}
{Location 2}
{#}
{Location 3}
{#}
{Location 4}
{#}
{Location 5}
{#}
{Location 6}
{#}
{Location 7}
{#}
{Location 8}
{#}
{Location 9}
{#}
{Location 10}
0
20
40
60
80
100
120
140
{Page break here}
Page 36 of 64
The average waist circumference for female {Company Name} employees is {#} cm. The ‘low’
cutoff is 89 cm for females.
Graph 29. Average Female Waist Circumference for {Company Name}
<90
'Low'
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
0
20
40
60
80
100
120
Graph 30. Average Female Waist Circumference by Location
{Location 1}
{#}
{Location 2}
{#}
{Location 3}
{#}
{Location 4}
{#}
{Location 5}
{#}
{Location 6}
{#}
{Location 7}
{#}
{Location 8}
{#}
{Location 9}
{#}
{Location 10}
{#}
0
20
40
60
80
100
120
{Page break here}
Page 37 of 64
Waist-Hip Ratio (WHR)
Considered in clinical research to be a better indicator of obesity-related health risk than body
mass index, waist-to-hip ratio is the circumference of the waist divided by the circumference of
the hips. A high waist-hip ratio indicates elevated abdomen fat, which is associated with
increased risk for hypertension, type 2 diabetes, high cholesterol, and heart disease. The waist
measurement is taken by using a cloth tape measure or string held at the hip bone, and wrapping
it around the abdomen, so that it is up against the skin without compressing it, at the narrowest
part (usually at or just above the level of the navel) The individual being measured should stand
with a straight and relaxed posture, arms hanging by their side. They should breathe normally
and not hold their breath or hold in their stomach. The hip measurement is taking by measuring
the distance around the hips at the widest part of the buttocks. The cutoff for increased risk in
males is 0.95, and 0.86 for females.12
Table 38. Male Waist-Hip Ratio Risk Stratification – Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
≤ 0.95
{#}
{#}
{#}
{#}
{#}
Normal
> 0.95
{#}
{#}
{#}
{#}
{#}
Very High Risk
Total
{#}
{#}
{#}
{#}
{#}
Table 39. Male Waist-Hip Ratio Risk Stratification – Percent
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
≤ 0.95
{%}
{%}
{%}
{%}
{%}
Normal
> 0.95
{%}
{%}
{%}
{%}
{%}
Very High Risk
Total
{%}
{%}
{%}
{%}
{%}
Table 40. Female Waist-Hip Ratio Risk Stratification – Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
≤ 0.86
{#}
{#}
{#}
{#}
{#}
Normal
> 0.86
{#}
{#}
{#}
{#}
{#}
Very High Risk
Total
{#}
{#}
{#}
{#}
{#}
Table 41. Female Waist-Hip Ratio Risk Stratification – Percent
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
≤ 0.86
{%}
{%}
{%}
{%}
{%}
Normal
> 0.86
{%}
{%}
{%}
{%}
{%}
Very High Risk
Total
{%}
{%}
{%}
{%}
{%}
{Page break here}
Page 38 of 64
The average waist-hip ratio for male {Company Name} employees is {#}. The cutoff for increased
risk is 0.95 for males.
Graph 31. Average Male Waist-Hip Ratio for {Company Name}
'Very High Risk' Cutpoint
<0.96
{#}
Screening {#}
Screening {#}
{#}
{#}
Screening {#}
Screening {#}
{#}
{#}
Screening {#}
0.00
0.20
0.40
0.60
0.80
1.00
1.20
Graph 32. Average Male Waist-Hip Ratio by Location
{Location 1}
{#}
{Location 2}
{#}
{Location 3}
{#}
{#}
{Location 4}
{#}
{Location 5}
{Location 6}
{#}
{Location 7}
{#}
{Location 8}
{#}
{#}
{Location 9}
{#}
{Location 10}
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
{Page break here}
Page 39 of 64
The average waist-hip ratio for female {Company Name} employees is {#}. The cutoff for
increased risk is 0.86 for females.
Graph 33. Average Female Waist-Hip Ratio for {Company Name}
'Very High Risk' Cutpoint
<0.87
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
Screening {#}
{#}
0.00
0.20
0.40
0.60
0.80
1.00
1.20
Graph 34. Average Female Waist-Hip Ratio by Location
{Location 1}
{#}
{Location 2}
{#}
{Location 3}
{#}
{Location 4}
{#}
{Location 5}
{#}
{Location 6}
{#}
{Location 7}
{#}
{Location 8}
{#}
{Location 9}
{#}
{Location 10}
0.00
{#}
0.20
0.40
0.60
0.80
1.00
1.20
{Page break here}
Page 40 of 64
Percent Body Fat
There are a number of methods for determining the percentage of the body that is composed of
fat tissue versus lean mass. Some procedures are more accurate than others. Generally
speaking, the more accurate the method, the more time and equipment required to complete the
procedure. The most widely accepted method offering the best combination of practicality and
accuracy is the skin fold test. This test is completed using a device called a caliper to take
subcutaneous fat thickness readings at specific locations on the body. The resulting
measurements are then entered into a regression equation designed to estimate body fat
percentage. The recommended body fat percentage for males is no more than 25 percent, and
nor more than 31 percent for females.13
Table 42. Male Percent Body Fat Risk Stratification – Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Category
≤ 2-5*%
{#}
{#}
{#}
{#}
{#}
Essential Fat
6% – 13%
{#}
{#}
{#}
{#}
{#}
Athlete
14% – 17%
{#}
{#}
{#}
{#}
{#}
Fit
18% – 25%
{#}
{#}
{#}
{#}
{#}
Acceptable
> 25%
{#}
{#}
{#}
{#}
{#}
Obese
Total
{#}
{#}
{#}
{#}
{#}
Table 43. Male Percent Body Fat Risk Stratification – Percent
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Category
≤ 2-5%
{%}
{%}
{%}
{%}
{%}
Essential Fat
6% – 13%
{%}
{%}
{%}
{%}
{%}
Athlete
14% – 17%
{%}
{%}
{%}
{%}
{%}
Fit
18% – 25%
{%}
{%}
{%}
{%}
{%}
Acceptable
> 25%
{%}
{%}
{%}
{%}
{%}
Obese
Total
{%}
{%}
{%}
{%}
{%}
*The A.C.E. guidelines do not account for the 5% value in men, and therefore this numeric value was added to the
‘essential fat’ range for the purposes of this report.
Page 41 of 64
Table 44. Female Percent Body Fat Risk Stratification – Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Category
10-13*%
{#}
{#}
{#}
{#}
{#}
Essential Fat
14% – 20%
{#}
{#}
{#}
{#}
{#}
Athlete
21% – 24%
{#}
{#}
{#}
{#}
{#}
Fit
25% – 31%
{#}
{#}
{#}
{#}
{#}
Acceptable
> 31%
{#}
{#}
{#}
{#}
{#}
Obese
Total
{#}
{#}
{#}
{#}
{#}
Table 45. Female Percent Body Fat Risk Stratification – Percent
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Category
10-13*%
{%}
{%}
{%}
{%}
{%}
Essential Fat
14% – 20%
{%}
{%}
{%}
{%}
{%}
Athlete
21% – 24%
{%}
{%}
{%}
{%}
{%}
Fit
25% – 31%
{%}
{%}
{%}
{%}
{%}
Acceptable
> 31%
{%}
{%}
{%}
{%}
{%}
Obese
Total
{%}
{%}
{%}
{%}
{%}
*The A.C.E. guidelines do not account for the 13% value in women, and therefore this numeric value was added to
the ‘essential fat’ range for the purposes of this report.
{Page break here}
Page 42 of 64
The average percent body fat for male {Company Name} employees is {#}%. The cutoff for
‘obesity’ is 25% for males.
Graph 35. Average Male Percent Body Fat for {Company Name}
'Obesity' Cutpoint
<26.0%
{#}
Screening {#}
Screening {#}
{#}
{#}
Screening {#}
Screening {#}
{#}
{#}
Screening {#}
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
35.0%
Graph 36. Average Male Percent Body Fat by Location
{Location 1}
{#}
{Location 2}
{#}
{Location 3}
{#}
{Location 4}
{#}
{Location 5}
{#}
{Location 6}
{#}
{Location 7}
{#}
{Location 8}
{#}
{Location 9}
{#}
{Location 10}
0.0%
{#}
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
{Page break here}
Page 43 of 64
The average percent body fat for female {Company Name} employees is {#}%. The cutoff for
‘obesity’ is 31% for females.
Graph 37. Average Female Percent Body Fat for {Company Name}
'Obesity' Cutpoint
<32.0%
Screening {#}
{#}
Screening {#}
{#}
{#}
Screening {#}
Screening {#}
{#}
Screening {#}
0.0%
{#}
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
35.0%
40.0%
Graph 38. Average Female Percent Body Fat by Location
{Location 1}
{#}
{Location 2}
{#}
{Location 3}
{#}
{Location 4}
{#}
{Location 5}
{#}
{Location 6}
{#}
{Location 7}
{#}
{Location 8}
{Location 9}
{Location 10}
0.0%
{#}
{#}
{#}
5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% 40.0%
{Page break here}
Page 44 of 64
Bone Mineral Density (T-Score)
Bone Mineral Density testing is an ultrasound scan that measures mineral levels within the bone,
indicating their density and strength. Stronger bones are less likely to break. Bone density is
measured using the Achilles machine which transmits ultrasound energy through the heel and
measures the bone mineral density at the heel. The machine calculates a “T-score” which
indicates the risk for osteoporosis. A T-score of greater than negative 1.0 indicates normal bone
density. Scores under negative 1.0 suggest low bone density, and under negative 2.5 indicates
possible osteoporosis or bone loss.14
Table 46. Bone Density (T-score) Stratification – Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Category
Above -1.0
{#}
{#}
{#}
{#}
{#}
Normal Bone Density
-1.0 – -2.5
{#}
{#}
{#}
{#}
{#}
Below Normal Density
Below -2.5
{#}
{#}
{#}
{#}
{#}
Osteoporosis/Bone Loss
Total
{#}
{#}
{#}
{#}
{#}
Table 47. Bone Density (T-score) Stratification – Percent
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Category
Above -1.0
{%}
{%}
{%}
{%}
{%}
Normal Bone Density
-1.0 – -2.5
{%}
{%}
{%}
{%}
{%}
Below Normal Density
Below -2.5
{%}
{%}
{%}
{%}
{%}
Osteoporosis/Bone Loss
Total
{%}
{%}
{%}
{%}
{%}
{Page break here}
Page 45 of 64
The average T-score for {Company Name} who participated in the Bone Mineral Density
screening is {#}. A t-score of greater than negative 1 indicates normal bone density.
Graph 39. Average Bone Density (T-score) for {Company Name}
'Normal'
-1.0
{#}
Screening {#}
Screening {#}
{#}
{#}
Screening {#}
Screening {#}
{#}
{#}
Screening {#}
-4.0
-3.0
-2.0
-1.0
0.0
1.0
2.0
Graph 40. Average Bone Density (T-score) by Location
{Location 1}
{#}
{Location 2}
{#}
{Location 3}
{#}
{Location 4}
{#}
{Location 5}
{#}
{Location 6}
{#}
{Location 7}
{#}
{Location 8}
{#}
{Location 9}
{#}
{Location 10}
-4.0
{#}
-3.0
-2.0
-1.0
0.0
1.0
2.0
{Page break here}
Page 46 of 64
BIOMETRICS SCREENING SUMMARY
The tables below provide a summary of the risk stratification for the biometric screening results
conducted at {Company Name} on {date(s)}.
Table 48. Systolic Blood Pressure Risk Stratification
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 120 mmHg
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Normal
120 – 139 mmHg
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Pre-Hypertensive
140 – 159 mmHg
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Stage 1 Hypertension
160 + mmHg
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Stage 2 Hypertension
Total
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Table 49. Diastolic Blood Pressure Risk Stratification
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 80 mmHg
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Normal
80 – 89 mmHg
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Pre-Hypertensive
90 – 99 mmHg
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Stage 1 Hypertension
100 + mmHg
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Stage 2 Hypertension
Total
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Table 50. Overall Blood Pressure Risk Stratification
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
Normal
Systolic: <120 mmHg
AND
Diastolic: <80 mmHg
Pre-Hypertensive
Systolic: 120–139 mmHg
OR
Diastolic: 80–89 mmHg
Hypertension, Stage-1
Systolic: 140–159 mmHg
OR
Diastolic: 90–99 mmHg
Hypertension, Stage-2
Systolic: 160+ mmHg
OR
Diastolic: 90+ mmHg
Total
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Page 47 of 64
Table 51. Resting Pulse
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Resting Pulse
40 – 59 bpm
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
60 – 100 bpm
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
> 100 bpm
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Total
Table 52. BMI Risk Stratification
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
< 18.5
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Underweight
18.5 – 24.9
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Normal
25 – 29.9
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Overweight
30 +
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Obese
35.0 – 39.9
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Obesity Class II
40.0 +
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Obesity Class III
Total
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Table 53. Waist Circumference Risk Stratification
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
Very Low
Male: < 80 cm
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Female: < 70 cm
Low
Male: 80 – 99 cm
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Female: 70 – 89 cm
High
Male: 100 – 120 cm
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Female: 90 – 109 cm
Very High
Male: > 120 cm
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Female: > 110 cm
Total
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Page 48 of 64
Table 54. Waist-Hip Ratio Risk Stratification
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Risk Category
Normal
Male:≤ 0.95
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Female: ≤ 0.86
High Risk
Male: > 0.95
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Female: > 0.86
Total
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Table 55. Percent Body Fat Risk Stratification
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Category
Essential Fat
Male: 2-5*%
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Female: 10-13*%
Athletes
Male: 6% – 13%
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Female: 14% – 20%
Fit
Male: 14% – 17%
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Female: 21% – 24%
Acceptable
Male: 18% – 25%
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Female: 25% – 31%
Obese
Male: > 25%
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Female: > 31%
Total
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
*The A.C.E. guidelines do not account for the 5% value in men and the 13% value in women, and therefore this
numeric value was added to the ‘essential fat’ range for the purposes of this report.
Table 56. Bone Density (T-score) Stratification
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Category
Above -1.0
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Normal Bone Density
-1.0 – -2.5
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Below Normal Density
Below -2.5
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Osteoporosis/Bone Loss
Total
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
{#} ({%})
Page 49 of 64
{COMPANY NAME}
PULMONARY ASSESSMENT
{Page break here}
Page 50 of 64
Lung Function
Lung (pulmonary) function testing is often used to determine how well the lungs are working.
These tests are useful for determining if there is a problem, such as a lung disease, and how
severe or progressive a current lung problem may be. Pulmonary function testing is
recommended for smokers over age 45 and persons with shortness of breath (dyspnea), chronic
coughing, wheezing, or excessive mucus production. Testing is done using a device called a
spirometer. This device has a mouthpiece the subject breaths into and can perform a number of
different test protocols. The device measures and records results and can often provide a quick
print out of this information.
Forced Vital Capacity (FVC)
The FVC protocol measures the amount of air exhaled after inhaling as deeply as possible.
Factors that can affect results include gender, body size, altitude, smoking history, fitness level,
and the existence of any current lung disease/condition such as asthma, chronic bronchitis,
chronic obstructive pulmonary disease (COPD), and emphysema. FVC can be used to determine
severity of a restrictive disease, when expressed as a percent of the predicted value, and using
the normative values table provided with the particular Spirometer being used. The Spirometer
may even have an internal microchip to interpret the results and provide a diagnosis. When a
person demonstrates an obstructive condition, the Total Lung Capacity (TLC) is often examined
to confirm the restrictive disorder.
Table 57. FVC Stratification by Stage– Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
12
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Stage
Normal
> lower limit of ‘Normal’
{#}
{#}
{#}
{#}
{#}
AND > 69% of predicted
Mild
FVC < ‘Normal’ limit, but
{#}
{#}
{#}
{#}
{#}
still > 69% of predicted
Moderate
FVC 60% – 69%
{#}
{#}
{#}
{#}
{#}
of predicted
Moderately Severe
FVC 50% – 59%
{#}
{#}
{#}
{#}
{#}
Of predicted
Severe
FVC 34% – 49%
{#}
{#}
{#}
{#}
{#}
of predicted
Very Severe
FVC < 34%
{#}
{#}
{#}
{#}
{#}
of predicted
Total
{#}
{#}
{#}
{#}
{#}
{Page break here}
Page 51 of 64
Peak Expiratory Flow Rate (PEFR)
This procedure is similar to the FVC where the participant inhales maximally and then exhales as
quickly and forcefully as possible. The difference is, rather than measuring the volume of air
expired as in a FVC test, the maximum force the air is expired with is determined. The test is
conducted using an inexpensive hand-held device called a peak flow meter, and is often
performed regularly by asthmatics or those who suffer from allergies. Typical protocol is to take
three readings and record the best of the three as the person’s PEFR. The American Lung
Association classifies results into three color-coded categories, fashioned after a standard traffic
light. The ‘Green Zone’ indicates breathing conditions are under control, while the ‘Yellow Zone’
indicates caution as the airway may be narrowing and additional medication needed. The ‘Red
Zone’ indicates a medical emergency where the airway is narrowing and a doctor or hospital
should be contacted immediately.15 Normal expected values depend on a person’s gender, age,
and height. The table below presents the frequency counts for {Company Name} employees who
participated in PEFR testing.
Table 58. PEFR Stratification by Zone– Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Zone
Green
80 to 100% of usual or
{#}
{#}
{#}
{#}
{#}
normal peak flow
Yellow
50% to 80% of usual or
{#}
{#}
{#}
{#}
{#}
normal peak flow
Red
< 50% of usual or normal
{#}
{#}
{#}
{#}
{#}
peak flow
{Page break here}
Page 52 of 64
Chronic Obstructive Pulmonary Disease (COPD) Risk Assessment
Severity of COPD can be assessed using two spirometry test values, Forced Vital Capacity (FVC)
and Forced Expiratory Volume in the first second of a maximum forceful exhale (FEV1). The
severity of the obstructive disease is determined by examining the percent of predicted value for
the FEV1, and also the FEV1 to FVC ratio. The table below presents the stages of severity, along
with the description, and the frequency counts within each for {Company Name} employees who
participated in this screening.
Table 59. COPD Severity Stratification by Stage– Frequency
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
12
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Stage
*0: At Risk
FEV1 ≥ 80% of predicted
{#}
{#}
{#}
{#}
{#}
FEV1/FVC ≥ 70%
I: Mild
FEV1 ≥ 80% of predicted
{#}
{#}
{#}
{#}
{#}
FEV1/FVC < 70%
**II: Moderate
FEV1 30-79% of predicted
{#}
{#}
{#}
{#}
{#}
FEV1/FVC < 70%
III: Severe
FEV1 < 30% of predicted
{#}
{#}
{#}
{#}
{#}
FEV1/FVC < 70%
*Presenting chronic symptoms: cough, sputum production, dyspnea
** IIA: FEV1 50-79% of predicted; IIB: FEV1 30-49% of predicted
{Page break here}
Page 53 of 64
Lung Age Assessment
This procedure involves the use of a spirometer to determine FEV1 (volume of air expired in the
first second of a maximum forceful exhale). However, rather than reporting the results as a
percent of predicted, the results are converted to say the lungs are functioning at an age in a
person’s life cycle. For example, a 30 year old smoker may be told their lugs are functioning as if
the person was a healthy 65-year old. Studies show that when smokers learn their lung age,
cessation rates increase significantly. The graph below illustrates the findings from Company
Name} employees who participated in the lung age assessment.
Graph 41. Average Age to Average Lung Age Comparison for {Company Name}
70
65
64
63
62
61
60
Years
50
40
35
36
35
37
36
38
37
39
38
39
28
29
30
31
27
Screening {#}
{Date} to {date}
Screening {#}
{Date} to {date}
Screening {#}
{Date} to {date}
Screening {#}
{Date} to {date}
Screening {#}
{Date} to {date}
30
20
10
0
Smokers Average Age
Smokers Average Lung Age
Non-Smokers Average Age
Non-Smokers Average Lung Age
Smoking
Smoking rates were determined for {Company Name} screening participants by using {Self
report; Cotinine [blood, urine or saliva] test}.
Table 60. Smoking and Non-Smokers for {Company Name} – Frequency and Percent
Screening {#} Screening {#} Screening {#} Screening {#} Screening {#}
{Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date} {Date} to {date}
Category
Non-Smoker
{# (%)}
{# (%)}
{# (%)}
{# (%)}
{# (%)}
Smoker
{# (%)}
{# (%)}
{# (%)}
{# (%)}
{# (%)}
{# (%)}
{# (%)}
{# (%)}
{# (%)}
{# (%)}
Total
{Page break here}
Page 54 of 64
The percent of {Company Name} employees who smoke is {#}%. In America, 21% of the
population smokes cigarettes.16
Graph 42. Percent of {Company Name} Employees Who Smoke
21.1%
U.S. Average
Screening {#}
{#}
{#}
Screening {#}
Screening {#}
{#}
{#}
Screening {#}
Screening {#}
{#}
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
Graph 43. Percent of Smokers by Location
{#}
{Location 1}
{#}
{Location 2}
{#}
{Location 3}
{Location 4}
{#}
{#}
{Location 5}
{#}
{Location 6}
{Location 7}
{#}
{#}
{Location 8}
{#}
{Location 9}
{#}
{Location 10}
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
{Page break here}
Page 55 of 64
HEALTHY PEOPLE 2010
Healthy People is a large nation-wide effort involving collaboration between Federal, State, and
territorial governments and several private, public, and nonprofit organizations. The initiative
operates in 10-year increments to provide national objectives for promoting health and preventing
disease. The current version has two broad goals:
1. Increase the quality and years of healthy life
2. Eliminate health disparities
The 2010 effort is composed of 467 health improvement objectives and 434 sub-objectives
across 28 Focus Areas listed below:
1. Access to Quality Health Services
15. Injury and Violence Prevention
2. Arthritis, Osteoporosis, and Chronic Back Conditions 16. Maternal, Infant, and Child Health
3. Cancer
17. Medical Product Safety
4. Chronic Kidney Disease
18. Mental Health and Mental Disorders
5. Diabetes
19. Nutrition and Overweight
6. Disability and Secondary Conditions
20. Occupational Safety and Health
7. Educational and Community-Based Programs
21. Oral Health
8. Environmental Health
22. Physical Activity and Fitness
9. Family Planning
23. Public Health Infrastructure
10. Food Safety
24. Respiratory Diseases
11. Health Communication
25. Sexually Transmitted Diseases
12. Heart Disease and Stroke
26. Substance Abuse
13. HIV
27. Tobacco Use
14. Immunizations and Infectious Diseases
28. Vision and Hearing
The objectives are in place to track the progress of our nation in achieving the Healthy People
2010 goals by the end of the decade, and planning is currently underway for the Healthy People
2020 framework.
As an organizational leader you are in a unique position to contribute to this effort by working to
improve the health status of your company employees. This section of the aggregate report
provides relevant objectives from Healthy People 2010 and compares them to the current health
status of {Company Name} participating employee sample. This information can be used to
evaluate the status of your employee health compared to national goals, and also to demonstrate
any health improvement program and company achievements.
Page 56 of 64
Healthy People 2010 – Focus Area 12: Heart Disease and Stroke
Objective 12.9: Reduce the proportion of adults with high blood pressure.
(Defined as a systolic of 140+ mmHg OR diastolic of 90+). Target: 16 percent.17
Graph 44. Percent of {Company Name} Employees Who Have High Blood Pressure
HP 2010 Objective
16%
{Company Name}
{#}
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
Objective 12.13: Reduce the mean total blood cholesterol levels among adults.17
Target: 199 mg/dL (mean).
Graph 45. Mean Total Blood Cholesterol for {Company Name} Employees
199 mg/dL
HP 2010 Objective
{Company Name}
170
{#}
175
180
185
190
195
200
205
Objective 12.14: Reduce the proportion of adults with ‘high’ total blood cholesterol levels.17
(Defined as a total cholesterol level of 240+ mg/dL). Target: 17 percent.
Graph 46. Percent of {Company Name} Employees Who Have High Total Cholesterol
HP 2010 Objective
17%
{Company Name}
0.0%
{#}
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
14.0%
16.0%
18.0%
Page 57 of 64
Healthy People 2010 – Focus Area 19: Nutrition and Overweight
Objective 19.1: Increase the proportion of adults who are at a healthy weight.17
(defined as a BMI of 18.5 - 25). Target: 60 percent.
Graph 47. Percent of {Company Name} Employees Who Have ‘Normal” BMI
HP 2010 Objective
60%
{Company Name}
52.0%
{#}
53.0%
54.0%
55.0%
56.0%
57.0%
58.0%
59.0%
60.0%
61.0%
Objective 19.2: Reduce the proportion of adults who are obese.17
(defined as a BMI of 30 or more). Target: 15 percent.
Graph 48. Percent of {Company Name} Employees Who Are ‘Obese”
HP 2010 Objective
15%
{Company Name}
14.0%
{#}
14.5%
15.0%
15.5%
16.0%
16.5%
17.0%
17.5%
Healthy People 2010 – Focus Area 27: Tobacco Use
Objective 27.1: Reduce tobacco use by adults.17
(Cigarette Smoking). Target: 12 percent.
Graph 49. Percent of {Company Name} Employees Who Smoke Cigarettes
HP 2010 Objective
12%
{Company Name}
0.0%
{#}
5.0%
10.0%
15.0%
20.0%
25.0%
Page 58 of 64
METABOLIC SYNDROME
It estimated that over 50 million Americans have metabolic syndrome, a condition characterized
by the presence of multiple metabolic risk factors within an individual.18 The American Heart
Association and the National Heart, Lung, and Blood Institute define metabolic syndrome as the
presence of three or more of the following five risk factors within an individual:
Elevated waist circumference:
Men — Equal to or greater than 40 inches (102 cm)
Women — Equal to or greater than 35 inches (88 cm)
Elevated triglycerides:
Equal to or greater than 150 mg/dL
Reduced HDL (“good”) cholesterol:
Men — Less than 40 mg/dL
Women — Less than 50 mg/dL
Elevated blood pressure:
Equal to or greater than 130/85 mm/Hg
Elevated fasting glucose:
Equal to or greater than 100 mg/dL
Metabolic syndrome is a great concern because people meeting the above definition have an
elevated risk of coronary heart disease and other diseases related to plaque build up in the
arteries. It is suggested that the synergistic effect from multiple risk factors act on the body in an
exponential fashion, and therefore placing a person at a much higher risk.
Metabolic syndrome is a great concern for health practitioners and employers alike. The medical
and productivity-loss costs associated with the individual risk factors are tremendous. When a
person has multiple risk factors that cost is likely to be even higher. Employers are recommended
to identify individuals with metabolic syndrome, and help them to seek treatment to reduce or
eliminate their respective risk factors. The graph below illustrates the number of employees who
participated in the {Company Name} health screening who meet the criteria noted above for
metabolic syndrome.
Graph 50. {Company Name} Employees Meeting Metabolic Syndrome Criteria
Present 3 risk factors
{#}
Present 4 risk factors
{#}
Present all 5 risk factors
{#}
0
5
10
15
20
25
30
Page 59 of 64
CRITICAL VALUE STATISTICS
Summit Health takes a stepwise approach towards patient referrals and distinguishes between
biometric values that are within normal limits, out of normal limits but less than critical, and those
that are within critical ranges. Patients whose fasting glucose, non-fasting glucose, or blood
pressure results fall within critical ranges (detailed below) are asked to sign an Immediate
Referral Form/Physician Contact Commitment acknowledging their out-of-range test results and
agreeing to seek immediate medical care from their primary care or family physician,
occupational or worksite healthcare provider, or an urgent care clinic.
For values within normal limits:
All patients are encouraged to share their screening results with their Primary Care or
Family Physician at their next checkup or appointment.
For values outside of normal limits, but less than critical:
1. Patients with cholesterol values outside normal limits (Total Cholesterol >200 mg/dL,
HDL <40 mg/dL, Triglycerides ≥150 mg/dL) are encouraged to schedule an
appointment with their physician to discuss results.
2. Patients with elevated Glucose (fasting 100-129 mg/dL, non-fasting 140-200 mg/dL)
and/or Blood Pressure (systolic 120-129 mmHg, diastolic 80-99 mmHg) are
encouraged to schedule an appointment with their physician to discuss results.
For critical values:
1. Patients with highly elevated Glucose (fasting >125 mg/dL or higher, non-fasting > 200
mg/dL or higher) and/or Blood Pressure (systolic 160 mmHg or higher, diastolic 100
mmHg or higher) sign an Immediate Referral Form/Physician Contact Commitment that
documents their commitment to seek immediate follow-up care with their physician.
2. Patients without a Primary Care Physician are referred to an Urgent Care Clinic,
Occupational Medicine Department, Emergency Room (if necessary), or similar facility.
The frequency tables in each screening section present the number of {Company Name}
employees who had critical values for the respective risk factor.
Page 60 of 64
DISCUSSION
This is the {#} year {Company Name} has completed an employee health screening with Summit Health.
Based on this year’s results {Company Name}’s five most prevalent conditions are:
1. {Condition 1} – [Prevalence rate %}
2. {Condition 2} – [Prevalence rate %}
3. {Condition 3} – [Prevalence rate %}
4. {Condition 4} – [Prevalence rate %}
5. {Condition 5} – [Prevalence rate %}
Currently, {Company Name} does not meet Healthy People 2010 objectives for the following:
• {List all conditions from HP 2010 section that the company is not meeting
•
•
•
It is crucial that {Company Name} place a strong emphasis on reducing the prevalence of their top 5 risks
and develop realistic goals towards meeting, or exceeding, Healthy People 2010 goals. By successfully
accomplishing these objectives {Company Name} will improve the health of the employee population,
while reducing health care costs and improving employee productivity. Additionally, {Company Name}
should focus health improvement efforts on individuals who meet the criteria for having metabolic
syndrome. The results from this assessment indicate {#} of {Company Name} employees have at least
three of the five risk factors, meeting the definition of metabolic syndrome.
The conditions with the lowest prevalence within {Company Name}, based on this assessment, are:
1.
2.
3.
Also, {Company Name} is meeting the following Healthy People 2010 objectives:
•
•
•
{TEXT OPTION FOR RETURNING SUMMIT ASSESSMENT CLIENTS:}
Data Comparison
Evaluating change is an important part of any health improvement program. It allows you to observe shifts
in population health, and can provide useful information for determining program achievements, areas
needing improvement, and program needs.
The last year {Company Name} completed the Summit health assessment and biometric screening {#}
employees participated, and this year the number of participants was {#}. This is {an increase, a decrease}
of {%}. Keep this variable in mind while reviewing the year-to-year comparison grid on the following page.
The first column on the left displays the metric, while the next two columns contrast the metrics values
from the previous and this most recent assessment. The fourth column displays the difference or change
from year to year. The final four columns indicate if the year-to-year difference within each metric is an
increase, a decrease, no change, or not applicable ({Company Name} did not participate in the particular
screening).
Page 61 of 64
N/A
No
Change
Decrease
Increase
Difference
{Year}
Metric
Total cholesterol – average
Total cholesterol – number of ‘High Risk’
HDL cholesterol – male average (an increase is good)
HDL cholesterol – female average (an increase is good)
HDL cholesterol – males number of ‘High Risk’
HDL cholesterol – females number of ‘High Risk’
HDL cholesterol – males and females number of ‘High Risk’
Cholesterol ratio (Total/HDL) – average ratio
Cholesterol ratio (Total/HDL) – number of ‘Increased Risk’
LDL cholesterol – average
LDL cholesterol – number of ‘High Risk’ or ‘Very High Risk’
Triglycerides – average
Triglycerides – number of ‘High Risk’
Triglycerides – number of ‘Very High Risk’
Fasting Glucose – average
Fasting Glucose – number of ‘Diabetic Indication’
Non-fasting Glucose – average
Non-fasting Glucose – number of ‘Diabetic Indication’
Hemoglobin A1c – average
Hemoglobin A1c – number of ‘Elevated Risk’
Systolic blood pressure – average
Diastolic blood pressure – average
Blood pressure – number of ‘Stage-1 or Stage-2 Hypertension’
Body mass index (BMI) – average
Body mass index (BMI) – number of ‘Overweight’
Body mass index (BMI) – number of ‘Obesity Class I’, II, or III
Resting pulse – average
Waist circumference – male average
Waist circumference – female average
Waist circumference – male number of ‘High Risk’ or ‘Very High Risk’
Waist circumference – female number of ‘High Risk’ or ‘Very High Risk’
Waist to hip ratio – male average
Waist to hip ratio – female average
Waist to hip ratio – male number of ‘Very High Risk’
Waist to hip ratio – female number of ‘Very High Risk’
Percent body fat – male average
Percent body fat – female average
Percent body fat – male number of ‘Obese’
Percent body fat – female number of ‘Obese’
Bone density (T-score) – average (an increase is good)
Bone density (T-score) – number of ‘Below Normal’
Bone density (T-score) – number of ‘Osteoporosis/Bone Loss’
Lung age – average
Lung function – force vital capacity (FVC) – number of ‘Severe’ or ‘Very
Severe’
Peak Expiratory Flow Rate (PEFR) – number in ‘Red’ zone
COPD Risk Assessment – number ‘Severe’
Cigarette smoking – number of employees
Cigarette smoking – percent of assessment participants
{Year}
Comparison grid for {Company Name} from {last yr} to {this year}.
Page 62 of 64
WHAT TO DO NEXT
Share Results with Senior Leadership
Results likely provide ongoing health improvement program justification, and may even
demonstrate the need for increased resource commitment. Keeping senior leaders informed on
health improvement program outcomes is a good way to maintain consistent program support.
Compare Assessment Results to Program Goals
Evaluating program outcomes guides the health improvement program effort. Determining what
goals have been met, and where additional work is still needed, allows a health improvement
program to accomplish results-driven changes. When old goals are met, new standards should
be developed to continue the progress.
Target Employees in High-Risk Areas
Employees with critical values should be targeted for program interventions. Participation in
lifestyle/disease management programming, health coaching, and other programming initiatives
help improve the health of the employee population. Employees meeting the criteria for metabolic
syndrome are at an increased risk for critical health incidents such as heart attack and stroke and
should be a focus of the health improvement effort.
Continue to Assess the Health of {Company Name} Employee Population
Employee populations are dynamic. It is important to constantly monitor population health to
identify areas of need, and evaluate the health improvement program.
Review Strategic Plan
Having updated health assessment and biometric results provide a good opportunity to revise the
organization strategic plan. Such a review can determine appropriate program mix, resource
allocation, feasible timelines, and the need for other evaluation outcome measures. In most cases
a third-party or peer review can provide valuable insight regarding suggested strategic plan
modifications.
Cost Outcomes
Having updated biometrics also presents an opportunity to plan out or provide additional
evaluation outcomes such as cost saving data related to percent of health care claims associated
with lifestyle, health-related productivity costs, presenteeism, and health related absence costs. It
is recommended that the evaluation strategy is part of the strategic plan. Having the evaluation
plan account for short- and longer-term outcomes ensures there is frequent cost outcomes data
to share with senior management.
For assistance with any of these next steps contact Summit Health.
Page 63 of 64
REFERENCES
1. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III). “ATP 3 Cholesterol Guidelines, NHLBI.” Retrieved
July 1, 2009: <http://www.nhlbi.nih.gov/guidelines/cholesterol/>
2. National Heart, Lung, and Blood Institute (NHLBI). “NHLBI, High Blood Cholesterol: What You
Need to Know.” Retrieved July 1, 2009:
<http://www.nhlbi.nih.gov/health/public/heart/chol/wyntk.htm>
3. American Heart Association (AHA). “What Your Cholesterol Levels Mean.” Retrieved July 1, 2009:
<http://www.americanheart.org/presenter.jhtml?identifier=183>
4. Centers for Disease Control and Prevention (CDC). Susan E. Schober et al., “High Serum Total
Cholesterol – An Indicator for Monitoring Cholesterol Lowering Efforts: U.S. Adults, 2005–2006,”
December 2007.” Retrieved July 1, 2009: <http://www.cdc.gov/nchs/data/databriefs/db02.pdf>
5. American Heart Association (AHA). “Cholesterol Ratio.” Retrieved July 1, 2009:
<http://www.americanheart.org/presenter.jhtml?identifier=4503>
6. American Diabetes Association (AHA). “Diabetes Information - American Diabetes Association.”
Retrieved July 1, 2009: <http://www.diabetes.org/about-diabetes.jsp>
7. American Diabetes Association (ADA). “Frequently Asked Questions about Pre-Diabetes American Diabetes Association.” Retrieved July 1, 2009: <http://www.diabetes.org/prediabetes/faq.jsp>
8. American Diabetes Association (ADA). “Checking Your Blood Glucose - All About Diabetes American Diabetes Association.” Retrieved July 1, 2009: <http://www.diabetes.org/type-2diabetes/blood-glucose-checks.jsp>
9. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC-7). “jnc7full.pdf.” Retrieved July 1, 2009:
<http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf>
10. Mayo Clinic. “Heart rate: What's normal? - MayoClinic.com.” Retrieved July 1, 2009:
<http://www.mayoclinic.com/health/heart-rate/an01906>
11. Centers for Disease Control and Prevention (CDC). “Healthy Weight: Assessing Your Weight: BMI:
About Adult BMI | DNPAO | CDC.” Retrieved July 1, 2009:
<http://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html>
12. American College of Sports Medicine (ACSM). ACSM's Guidelines for Exercise Testing and
Prescription, 7th Edition; 2006.
13. American Council on exercise (A.C.E.). “Body Fat Measurement: Percentage vs. Body Mass.”
Retrieved July 1, 2009: <http://www.webmd.com/diet/features/body-fat-measurement?page=2>
14. Mayo Clinic. “Bone density test: Results - MayoClinic.com.” Retrieved July 1, 2009:
<http://www.mayoclinic.com/health/bone-density-test/MY00304/DSECTION=results>
15. American Lung Association (ALA). “Peak Flow Meters - American Lung Association site.” Retrieved
July 1, 2009:
<http://www.lungusa.org/site/c.dvLUK9O0E/b.22586/k.A7C2/Peak_Flow_Meters.htm>
16. American Heart Association (AHA). “Cigarette Smoking Statistics.” Retrieved July 1, 2009:
<http://www.americanheart.org/presenter.jhtml?identifier=4559>
17. Office of Disease Prevention and Health Promotion, - U.S. Department of Health and Human
Services. “Healthy People 2010 Online Documents.” Retrieved July 1, 2009:
<http://www.healthypeople.gov/Document/>
18. American Heart Association (AHA). : “Metabolic Syndrome.” Retrieved July 1, 2009:
<http://www.americanheart.org/presenter.jhtml?identifier=4756>
19. Leutzinger, J., Pirner, M., Landschulz, W., Nevins, R.L., Sullivan, S. & Silberman, C. (2006)
Metabolic syndrome and worksite health promotion. The Art of Health Promotion,
September/October, 1-11.
Page 64 of 64